The JoPIC is an independent-unbiased, peer-reviewed, and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, surgical techniques, differential diagnoses, editorial opinions, letters to the editor, and educational papers in pulmonology, thoracic surgery, occupational diseases, allergology, and intensive care medicine. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
Diagnostic value of tumor m2-pyruvate kinase level in lung cancer and its relationship with tumor histological type
Aims: To investigate the diagnostic value of purivate kinase isoenzyme-M2 (M2-PK) levels and their relationship with tumor histological type in patients diagnosed with lung cancer.
Methods: In this prospective study, 98 cases diagnosed with lung cancer (Study group) and 90 cases with lung cancer excluded (Control group) were included. The study group consisted of people over the age of 18 who had been diagnosed with lung cancer and had not received any treatment for the tumor. The control group consisted of 45 people who had been diagnosed with any lung disease but did not have lung cancer, and 45 of them were completely healthy people. Those with benign lung disease apart from lung cancer were named as control group-1 and healthy control group was named as control-group-2. Plasma samples with 5 cc of EDTA were taken from all subjects and these samples were quickly frozen at – 80 degrees and stored in this way until laboratory analysis could be performed. Commercial kit based on the sandwich ELISA principle (ScheBo Biotech Ag, Tumor M2-PK ELISA kit, Germany) was used to determine plasma M2-PK levels. The M2-PK values of the samples were calculated on the basis of the standard graph.
Results: M2-PK levels were measured and compared in the lung cancer group, control group-1 with non-lung cancer lung disease and healthy control group-2. M2-PK levels were found to be significantly higher in the lung cancer group than in the control group-1 (p<0.0001) and control-group-2 (p<0.0001). When M2-PK levels were compared in all three groups, they were statistically significant in the lung cancer group (p<0.001). In our study, the diagnostic cut off value was found to be 8.9 IU/ml using ROC curve. At this cut-off value, plasma m2-pk level was calculated as 100% sensitivity and 97.8% specificity in showing lung cancer. When compared, there was no statistically significant difference between histopathological diagnoses, stage of the disease and M2-PK levels in the lung cancer group.
Conclusion: As a result of this study, it has been shown that tumor M2-PK can be used in the differentiation of lung cancers from other benign lung lesions and as a marker in patients with suspected lung cancer.

1. Global Cancer Observatory. World Health Organization. Availableonline:https://gco.iarc.frAccessed 30 December, 2020.
2. Teker AG, Ay P. Has the cancer-related death trend been changing inTurkiye? An evaluation of the period between 2009 and 2019.CancerEpidemiol. 2022;80:102228.
3. Hung RJ. Biomarker-based lung cancer screening eligibility:ımplementation considerations.Cancer Epidemiol Biomarkers Prev.2022;31(4):698-701.
4. Zhang T, Liu W, Li L, Jue Z, Xu C. Evaluation of serum and pleurallevels tumor M2-pyruvate kinase in lung cancer patients with pleuraleffusion.BMC Pulm Med. 2022;22(1):307.
5. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase typeM2 and its role in tumor growth and spreading.Semin Cancer Biol.2005;15(4):300-308.
6. Zhang B, Chen JY, Chen DD, Wang GB, Shen P. Tumor type M2 pyruvatekinase expression in gastric cancer, colorectal cancer and controls.WorldJ Gastroenterol. 2004;10(11):1643-1646.
7. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolicbudget system in tumor cells.Int J Biochem Cell Biol. 2011;43(7):969-980.
8. Mazurek S, Zwerschke W, Jansen-D&uuml;rr P, Eigenbrodt E. Metaboliccooperation between different oncogenes during cell transformation:interaction between activated ras and HPV-16 E7.Oncogene. 2001;20(47):6891-6898.
9. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for theyear 2020: an overview.Int J Cancer. 2021;149(4):778-789.
10. Panunzio A, Sartori P. Lung cancer and radiological imaging.CurrRadiopharm. 2020;13(3):238-242.
11. Moyer VA, US Preventive Services Task Force. Screening for lung cancer:US Preventive Services Task Force recommendation statement.AnnIntern Med. 2014;160(5):330-338.
12. Brenner DJ. Radiation risks potentially associated with low-dose CTscreening of adult smokers for lung cancer.Radiol. 2004;231(2):440-445.
13. Oremek GM, M&uuml;ller R, Sapoutzis N, Wigand R. Pyruvate kinasetype tumor M2 plasma levels in patients afflicted with rheumaticdiseases.Anticancer Res. 2003;23(2A):1131-1134.
14. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 spliceisoform of pyruvate kinase is important for cancer metabolism andtumour growth.Nature. 2008;452(7184):230-233.
15. Sapoutzis N, Oremek GM. Evaluation of tumor M2 pyruvatekinasevalues in patients with lung diseases. 8th Central European Lung CancerConference, Vienna, Austria, September 1-4, 2002:75-80.
16. Kaura B, Bagga R, Patel FD. Evaluation of the pyruvate kinase isoenzymetumor (Tu M2-PK) as a tumor marker for cervical carcinoma.J ObstetGynaecol Res. 2004;30(3):193-196.
17. Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L. TumorM2-pyruvate kinase, a new metabolic marker for pancreatic cancer.DigDis Sci. 2004;49(7):1149-1155.
18. Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW,Siriwardena AK. Diagnostic and prognostic value of plasma tumor M2pyruvate kinase in periampullary cancer: evidence for a novel biologicalmarker of adverse prognosis.Pancreas. 2007;34(3):318-324.
19. Zhao R, Li L, Yang J, et al. Overexpression of pyruvate kinase M2in tumor tissues is associated with poor prognosis in patients withhepatocellular carcinoma.Pathol Oncol Res. 2020;26(2):853-860.
20. Li L, Zhang Q, Wang Y, Xu C. Evaluating the diagnostic and prognosticvalue of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer.JClin Lab Anal. 2023;37(7):e24865.
21. Xu C, Liu W, Li L, Wang Y, Yuan Q. Serum tumour M2-pyruvate kinaseas a biomarker for diagnosis and prognosis of early-stage non-small celllung cancer.J Cell Mol Med. 2021;25(15):7335-7341.
22. Liu J, Zhu H, Jiang H, et al. Tumor M2 pyruvate kinase in diagnosis ofnonsmall cell lung cancer: a meta-analysis based on Chinese population.JCancer Res Ther. 2015;11(Suppl 1):S104-S106.
Volume 2, Issue 1, 2024
Page : 6-10